IMC Chicago
CRSP icon

IMC Chicago’s CRISPR Therapeutics CRSP Stock Holding History

IMC Chicago’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15M Sell
314,900
-165,000
-34% -$8.7M 0.01% 1007
2025
Q4 		$25.2M Buy
479,900
+84,300
+21% +$5.05M 0.01% 745
2025
Q3 		$25.6M Sell
395,600
-120,600
-23% -$6.92M 0.01% 681
2025
Q2 		$25.1M Buy
516,200
+281,800
+120% +$10.9M 0.01% 606
2025
Q1 		$7.98M Buy
234,400
+6,000
+3% +$254K ﹤0.01% 983
2024
Q4 		$8.99M Buy
228,400
+95,400
+72% +$4.5M ﹤0.01% 952
2024
Q3 		$6.25M Sell
133,000
-16,100
-11% -$817K ﹤0.01% 1035
2024
Q2 		$8.05M Buy
149,100
+57,100
+62% +$3.3M ﹤0.01% 864
2024
Q1 		$6.27M Sell
92,000
-98,100
-52% -$7.02M ﹤0.01% 887
2023
Q4 		$11.9M Buy
190,100
+32,700
+21% +$1.81M 0.01% 599
2023
Q3 		$7.14M Sell
157,400
-10,200
-6% -$527K 0.01% 650
2023
Q2 		$9.41M Sell
167,600
-19,200
-10% -$1.09M 0.01% 523
2023
Q1 		$8.45M Buy
186,800
+20,400
+12% +$991K 0.01% 529
2022
Q4 		$6.76M Sell
166,400
-14,300
-8% -$759K 0.01% 542
2022
Q3 		$11.8M Sell
180,700
-28,800
-14% -$2.09M 0.02% 409
2022
Q2 		$12.7M Buy
209,500
+87,200
+71% +$5.13M 0.02% 381
2022
Q1 		$7.68M Buy
122,300
+15,600
+15% +$980K 0.01% 507
2021
Q4 		$8.09M Buy
106,700
+5,200
+5% +$454K 0.01% 523
2021
Q3 		$11.4M Buy
101,500
+2,200
+2% +$276K 0.01% 468
2021
Q2 		$16.1M Buy
99,300
+1,300
+1% +$158K 0.02% 378
2021
Q1 		$11.9M Buy
+98,000
New +$14.8M 0.02% 402

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

IMC Chicago's CRSP Position: Q3 2025 in Review

IMC Chicago sold out of CRISPR Therapeutics (CRSP) in Q3 2025, closing a stake of 23,080 shares — an estimated $1.33M sold.

IMC Chicago first reported a position in CRSP in Q1 2021 and held it in 14 quarters. The position peaked at $3.49M in Q4 2021. 440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

  • IMC Chicago reported no remaining CRISPR Therapeutics position as of Q3 2025 after selling out during the quarter.
  • IMC Chicago sold 23,080 CRISPR Therapeutics shares in Q3 2025, an estimated $1.33M.
  • IMC Chicago first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 14 quarters.
  • IMC Chicago's CRISPR Therapeutics position peaked at $3.49M in Q4 2021.
  • 440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on IMC Chicago's 13F filing for Q3 2025, filed 4 Nov 2025.